| Literature DB >> 31926135 |
Mengze Zhou1, Weiwei Wang2, Yehong Li1, Qian Zhang1, Hui Ji1, Huanqiu Li3, Qinghua Hu4.
Abstract
As a member of the P2Y receptor family with a typical 7-transmembrane structure, P2Y6 purinergic receptor (P2Y6R) belongs to the G-protein-coupled nucleotide receptor activating the phospholipase-C signaling pathway. P2Y6R is widely involved in a range of human diseases, including atherosclerosis and other cardiovascular diseases, gradually attracting attention owing to its inappropriate or excessive activation. In addition, it was reported that P2Y6R might regulate inflammatory responses by governing the maturation and secretion of proinflammatory cytokines. Hence, several P2Y6R antagonists have been subjected to evaluation as new therapeutic strategies in recent years. This review was aimed at summarizing the role of P2Y6R in the pathogenesis of cardiovascular diseases, with an insight into the recent progress on discovery of P2Y6R antagonists.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31926135 DOI: 10.1016/j.drudis.2019.12.015
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851